Login to Your Account

Serono In-Licenses Newron Parkinson's Drug For $200M

By Cormac Sheridan

Tuesday, October 17, 2006
Completing one last deal before finalizing its merger with Merck KGaA, Serono SA gained exclusive rights from Newron Pharmaceuticals SpA to safinamide, a compound undergoing a Phase III trial in Parkinson's disease, for up to $200 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription